To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Leukocyte-Rich vs. Leukocyte-Poor PRP Injections for Knee Osteoarthritis

Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
February 2025

Leukocyte-Rich vs. Leukocyte-Poor PRP Injections for Knee Osteoarthritis

Vol: 307| Issue: 2| Number:60| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Leukocytes Do Not Influence the Safety and Efficacy of Platelet-Rich Plasma Injections for the Treatment of Knee Osteoarthritis: A Double-Blind Randomized Controlled Trial.

Am J Sports Med. 2024 Nov;52(13):3212-3222.

Contributing Authors:
I Romandini A Boffa A Di Martino L Andriolo A Cenacchi E Sangiorgi S Orazi V Pizzuti S Zaffagnini G Filardo

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

One hundred thirty-two patients with Kellgren-Lawrence grade 1-3 knee osteoarthritis were randomized to receive three weekly intra-articular injections of either LR-PRP (n=66) or LP-PRP (n=66). The primary outcome was the change in the International Knee Documentation Committee (IKDC) subjective score at 12 months. Secondary outcomes included pain, function, and quality of life assessed through va...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue